This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Community Health (CYH) and Pelthos Therapeutics (PTHS)

Tipranks - Tipranks - Mon Mar 23, 8:22AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Community Health (CYH) and Pelthos Therapeutics (PTHS) with bullish sentiments.

Claim 30% Off TipRanks Premium

Community Health (CYH)

In a report issued on March 20, Michael Wiederhorn from Oppenheimer maintained a Buy rating on Community Health. The company’s shares closed last Friday at $2.89, close to its 52-week low of $2.53.

According to TipRanks.com, Wiederhorn is a 5-star analyst with an average return of 9.2% and a 57.7% success rate. Wiederhorn covers the Healthcare sector, focusing on stocks such as Guardian Pharmacy Services, Inc. Class A, The Ensign Group, and HCA Healthcare. ;'>

The word on The Street in general, suggests a Hold analyst consensus rating for Community Health with a $3.64 average price target, representing a 21.7% upside. In a report issued on March 18, TipRanks – DeepSeek also upgraded the stock to Buy with a $3.50 price target.

See Insiders’ Hot Stocks on TipRanks >>

Pelthos Therapeutics (PTHS)

Piper Sandler analyst David Amsellem reiterated a Buy rating on Pelthos Therapeutics on March 20 and set a price target of $48.00. The company’s shares closed last Friday at $20.74.

According to TipRanks.com, Amsellem is a 4-star analyst with an average return of 6.5% and a 50.9% success rate. Amsellem covers the Healthcare sector, focusing on stocks such as Supernus Pharmaceuticals, Collegium Pharmaceutical, and Fennec Pharmaceuticals. ;'>

Pelthos Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $58.33, a 158.8% upside from current levels. In a report issued on March 20, Roth MKM also maintained a Buy rating on the stock with a $55.00 price target.

Read More on CYH:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).